A systematic review of immune checkpoint inhibitors in endometrial cancer
-
By
-
Na Zhu
-
Chaihong Zhang
-
June 8, 2026
-
Clinical Scorecard: A comprehensive analysis of immune checkpoint inhibitors in the treatment of endometrial cancer
At a Glance
| Category | Detail |
|---|
| Condition | Endometrial cancer |
| Key Mechanisms | Immune checkpoint inhibitors targeting PD-1 and PD-L1 pathways |
| Target Population | Patients with endometrial cancer, particularly those with microsatellite instability or mismatch repair deficiency |
| Care Setting | Oncology clinics and research institutions |
Key Highlights
- Endometrial cancer is a prevalent gynecological malignancy with increasing incidence.
- Current research hotspots include microsatellite instability, mismatch repair deficiency, and immune checkpoint inhibitors.
- The TCGA molecular typing system is transforming treatment approaches for endometrial cancer.
- Pembrolizumab, lenvatinib, and dostarlimab are significant emerging therapies.
- The United States, China, and Italy are leading contributors to research in this field.
Guideline-Based Recommendations
Diagnosis
- Utilize the TCGA molecular typing system for prognosis assessment.
Management
- Consider immune checkpoint inhibitors as novel therapeutic alternatives for advanced or recurrent endometrial cancer.
Monitoring & Follow-up
- Track tumor mutational burden and mismatch repair status for treatment efficacy.
Risks
- Traditional treatment methods may have limited efficacy in advanced or recurrent cases.
Patient & Prescribing Data
Patients diagnosed with endometrial cancer, especially those with dMMR or MSI-H.
Immune checkpoint inhibitors show significant sensitivity in treating endometrial cancer.
Clinical Best Practices
- Adopt a precision treatment approach guided by molecular characteristics.
- Integrate immunotherapy into treatment plans for advanced endometrial cancer.
Related Resources & Content
